- PERSONALIZED CARE
April 1, 2003
Imatinib: Patients with Chronic Myeloid Leukemia Have New Alternative when Transplantation Is Not Feasible
In patients with newly diagnosed chronic myeloid leukemia (CML) who are not suitable candidates for hematopoietic stem-cell transplantation, imatinib mesylate (Gleevec—Novartis) is emerging as...
February 1, 2003PREVIEW
Complete endocrine blockade—achieved with goserelin (Zoladex—AstraZenece) administration for 3 years and tamoxifen (Nolvadex—AstraZeneca) therapy for 5 years—is superior to standard chemotherapy...
November 1, 2002PREVIEW
While prophylactic tamoxifen reduces the risk of breast cancer by about one-third, its overall risk-to-benefit ratio remains unclear, according to a study of 7,152 women. Editorialists,...
September 1, 2002PREVIEW
The colorectal cancer drug oxaliplatin (Eloxatin—Sanofi-Synthélabo) is now available for use in the United States.
August 1, 2002PREVIEW
For women with hormone-receptor–positive breast cancer, a 5-year course of adjuvant tamoxifen remains the standard therapy, according to an evidence-based technology assessment of aromatase...